Abstract:Background: Previous studies have reported conflicting results on the association between metformin and risk of dementia which might be caused by varied drug responses of metformin in different population subgroups. We aimed to examine the heterogeneous treatment effects (HTEs) of metformin on dementia risk in the population with type 2 diabetes (T2D). Method: Using 2005-2021 data from the National Alzheimer’s Coordinating Center (NACC), we identified individuals with diabetes (≥50 years old, ≥2 clinic visits) and normal cognition at baseline. The primay outcome was incident dementia. We applied a causal machine learning approach - doubly robust learning - to estimate the conditional average treatment effects (CATEs) in the overall cohort and then the HTE subgroups based on the identified important features using a summary decision tree model. Results: Of 1,505 individuals with T2D, 822 (55%) were taking metformin at baseline and 683 (45%) were not. 109 participants (7.2%) developed dementia over a median follow-up of 4.0 years. In the estimation of CATEs in the overall cohort, metformin was associated with a lower risk of dementia (Risk difference [RD], -2.9%; 95% confidence interval [CI], -5.9% to -0.002%). We identified four subgroups with varied risks for dementia in those on metformin therapy, defined by neuropsychiatric disorders, alcohol abuse, and antidepressant use. Metformin was significantly associated with a lower risk of dementia in the subgroup with no neuropsychiatric disorders and no alcohol abuse (-5.9%; -9.6% to -2.3%); however, it was associated with a greater risk in those with neuropsychiatric disorders and no antidepressant use (7.4%; 0.8% to 14.0%). Conclusion: Metformin use was significantly associated with lower risk of dementia in individuals with T2D, with significant variability among subgroups. Data-driven subgroup analyses may guide personalized treatment for diabetes care. Disclosure H.Tang: None. J.Guo: Consultant; Pfizer Inc., Research Support; PhRMA Foundation, NIH - National Institutes of Health. C.Shaaban: None. Z.Feng: None. Y.Wu: None. T.Magoc: None. W.T.Donahoo: None. S.T.Dekosky: Advisory Panel; Acumen Pharmaceuticals, Cognition Therapeutics, Other Relationship; Biogen, Prevail Pharmaceuticals, UpToDate, Up-To-Date. J.Bian: None. Funding National Institute on Aging (1R01AG076234-01); National Institute of Diabetes and Digestive and Kidney Diseases (R01DK133465)

Association of metformin exposure with low risks of frailty and adverse outcomes in patients with diabetes

The impact of frailty on clinical outcomes among older adults with diabetes: A systematic review and meta-analysis

Metformin Use and Risk of Delirium in Older Adults With Type 2 Diabetes

Impact of frailty on mortality, hospitalization, cardiovascular events, and complications in patients with diabetes mellitus: a systematic review and meta-analysis

Metformin in aging and aging-related diseases: clinical applications and relevant mechanisms

The Association Between Metformin Treatment and Outcomes in Type 2 Diabetes Mellitus Patients With Heart Failure With Preserved Ejection Fraction: A Retrospective Study

Metformin Is Associated With Slightly Reduced Risk Of Colorectal Cancer And Moderate Survival Benefits In Diabetes Mellitus: A Meta-Analysis

Metformin use is associated with low risk of case fatality and disability rates in first-ever stroke patients with type 2 diabetes

Prediabetes Increases the Risk of Frailty in Older Adults With Prefrail Hypertension: Beneficial Effects of Metformin

Metformin: An Old Drug with New Applications

Metformin in elderly type 2 diabetes mellitus: dose-dependent dementia risk reduction

Association of metformin and depression in patients with type 2 diabetes

Association of metformin use with ovarian cancer incidence and prognosis: a systematic review and meta-analysis

A Clinical Perspective of the Multifaceted Mechanism of Metformin in Diabetes, Infections, Cognitive Dysfunction, and Cancer

Lead Exposure and Physical Frailty in Patients with Type 2 Diabetes Mellitus: Cross-Sectional Results from the METAL Study

The effect of metformin on senescence of T lymphocytes

Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study

Metformin as a Potential Prevention Strategy for Alzheimer's Disease and Alzheimer's Disease Related Dementias

Heterogeneous treatment effects of metformin on the risk of dementia in people with type 2 diabetes: A longitudinal observational study

Relationship of Metformin with the Risk of Pancreatic Cancer in Patients with Type 2 Diabetes: a Meta-Analysis

Metformin for Cardiovascular Protection, Inflammatory Bowel Disease, Osteoporosis, Periodontitis, Polycystic Ovarian Syndrome, Neurodegeneration, Cancer, Inflammation and Senescence: What Is Next?